Close
Nordic 9Nordic 9

Redmile Group (investor - Others)

United States redmilegroup.com
See something wrong or missing? Let us know
Offices:San Francisco

Redmile Group is an American hedge fund that does early-stage venture, later stage venture, private equity and post IPO equity investments.

Average round investment:58.1M USD
Average number per year:1.5
Distribution: 2025 (1)2024 (1)2023 (1)2021 (3)
Portfolio companies: France One BiosciencesBelgium AgomabFrance Sensorion See the entire list
Mostly invests in: France France (3) Biotech (5)
See the entire list

Showing 3 of 6 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Redmile Group mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Redmile Group

Name Criteria
United States HOF Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland Korify Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Japan Mitsubishi Corp
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Cormorant Asset Management
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Netherlands Partners in Equity
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Software Services, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Switzerland Pictet Group
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Software Services, Pharma
  • Similar business models: B2B
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States venBio Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Emerson Collective
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Research Corporation Technologies
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Singapore EDBI
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top